Brenda Shanahan AO served in senior executive and board roles in Australia and overseas primarily in stockbroking, funds management and investment consulting.
She is a director of Clinuvel Pharmaceuticals, Bell Financial Group, Phoslock Environment Technologies, and DMP Asset Management. She is also a member of Swinburne University Industry Advisory Board, and the Australian Advisory Board on Technology and Healthcare Competitiveness.
Ms Shanahan was chair of St Vincent’s Institute of Medical Research and is a member of the SVI Foundation. She was a director of Challenger Limited, member of the Australian Stock Exchange, partner of May Mellor Laing & Cruikshank, principal of Investment Consulting, and worldwide partner at WM Mercer.
In 2021, Ms Shanahan was awarded an Officer of the Order of Australia for distinguished services to medical health research, to the business and finance sectors, to corporate governance, and to philanthropy.
